GLAXF News and Press, GlaxoSmithKline Plc From 11/02/22

GSK plc (GSK) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Debo...

Summary My portfolio, built specifically for my retirement ~20+ years from now, invested a new large position in a beaten down big tech stock. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a...

Summary Third Point recently acquired a significant position in Colgate-Palmolive. The investment fits several important criteria in the current investment environment. The stage is set for Colgate to deliver several years of outsized earnings growth. Colgate’s valu...

Summary Third Point LLC is an SEC-registered investment adviser based in New York. The firm was founded in 1995 by Daniel S. Loeb, who serves as Chief Executive Officer. Third Point focuses on event-driven, value-oriented investing. During the Third Quarter, Third Point returned -...

Summary Updated results from Part A of the phase 2 MARCH study using both VIR-2218 and VIR3434 for Hepatitis B treatment are expected in the 2nd half of 2022. Results from the ongoing phase 2 study using VIR-2218 alone as a monotherapy and in combination with PEG-IFN-a for Hepatit...

Summary Investors are flocking to USD, and most foreign currencies are now weak. On the surface, investment implications seem slight, but it is quite the contrary. This article will highlight the current market implications and ways that a strong USD influences foreign assets....

Summary Sartorius stock has corrected by 55% over the last 12 months, visibly underperforming its peers and the pharmaceutical companies. Despite this, we rate the shares as neutral and stay on the sidelines until order visibility improves. We believe that the business will co...

Summary Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimer's Disease, in the ongoing INVOKE-2 phase 2 study. The ...

Summary Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per share, associated with Phase 3 clinical trial provides sufficient upside fro...

Summary The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position. At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Lucentis, which is a medicine used to treat patients with certain. Teva P...